These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21839809)

  • 1. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.
    Fletcher AM; Kowalczyk TH; Padegimas L; Cooper MJ; Yurek DM
    Neuroscience; 2011 Oct; 194():220-6. PubMed ID: 21839809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and lesion-induced increases of GDNF transgene expression in brain following intracerebral injections of DNA nanoparticles.
    Yurek DM; Hasselrot U; Cass WA; Sesenoglu-Laird O; Padegimas L; Cooper MJ
    Neuroscience; 2015 Jan; 284():500-512. PubMed ID: 25453772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration.
    Yurek D; Hasselrot U; Sesenoglu-Laird O; Padegimas L; Cooper M
    Nanomedicine; 2017 Oct; 13(7):2209-2217. PubMed ID: 28666950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons.
    Yurek DM; Flectcher AM; Kowalczyk TH; Padegimas L; Cooper MJ
    Cell Transplant; 2009; 18(10):1183-96. PubMed ID: 19650971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.
    Xia CF; Boado RJ; Zhang Y; Chu C; Pardridge WM
    J Gene Med; 2008 Mar; 10(3):306-15. PubMed ID: 18085726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
    Connor B
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism.
    Chen SS; Yang C; Hao F; Li C; Lu T; Zhao LR; Duan WM
    Exp Neurol; 2014 Nov; 261():87-96. PubMed ID: 24997241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.
    Huang R; Ke W; Liu Y; Wu D; Feng L; Jiang C; Pei Y
    J Neurol Sci; 2010 Mar; 290(1-2):123-30. PubMed ID: 19909981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease.
    Aly AE; Harmon BT; Padegimas L; Sesenoglu-Laird O; Cooper MJ; Waszczak BL
    Mol Neurobiol; 2019 Jan; 56(1):688-701. PubMed ID: 29779176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.
    Zhang Y; Pardridge WM
    Pharm Res; 2009 May; 26(5):1059-63. PubMed ID: 19104914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
    Duan D; Yang H; Zhang J; Zhang J; Xu Q
    Exp Brain Res; 2005 Mar; 161(3):316-24. PubMed ID: 15480595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term transgene expression in the central nervous system using DNA nanoparticles.
    Yurek DM; Fletcher AM; Smith GM; Seroogy KB; Ziady AG; Molter J; Kowalczyk TH; Padegimas L; Cooper MJ
    Mol Ther; 2009 Apr; 17(4):641-50. PubMed ID: 19223866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain.
    Aly AE; Harmon B; Padegimas L; Sesenoglu-Laird O; Cooper MJ; Yurek DM; Waszczak BL
    Nanomedicine; 2019 Feb; 16():20-33. PubMed ID: 30472323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
    Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
    Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease.
    Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X
    Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
    Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
    Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
    Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
    Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.